These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

617 related articles for article (PubMed ID: 28241268)

  • 21. The consequences of delayed diagnosis and treatment in persons with multiple sclerosis given autologous hematopoietic stem cell transplantation.
    Pastelín-Martínez ML; Gallardo-Pérez MM; Gómez-de-León A; Olivares-Gazca JC; Hernández-Flores EJ; Sánchez-Bonilla D; Montes-Robles M; Robles-Nasta M; Ocaña-Ramm G; Soto-Olvera S; Gómez-Almaguer D; Ruiz-Delgado GJ; Ruiz-Argüelles GJ
    Diagnosis (Berl); 2024 May; 11(2):164-170. PubMed ID: 38230519
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience.
    Burman J; Iacobaeus E; Svenningsson A; Lycke J; Gunnarsson M; Nilsson P; Vrethem M; Fredrikson S; Martin C; Sandstedt A; Uggla B; Lenhoff S; Johansson JE; Isaksson C; Hägglund H; Carlson K; Fagius J
    J Neurol Neurosurg Psychiatry; 2014 Oct; 85(10):1116-21. PubMed ID: 24554104
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial.
    Atkins HL; Bowman M; Allan D; Anstee G; Arnold DL; Bar-Or A; Bence-Bruckler I; Birch P; Bredeson C; Chen J; Fergusson D; Halpenny M; Hamelin L; Huebsch L; Hutton B; Laneuville P; Lapierre Y; Lee H; Martin L; McDiarmid S; O'Connor P; Ramsay T; Sabloff M; Walker L; Freedman MS
    Lancet; 2016 Aug; 388(10044):576-85. PubMed ID: 27291994
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Autologous hematopoietic stem cell transplantation significantly alters circulating ceramides in peripheral blood of relapsing-remitting multiple sclerosis patients.
    Vaivade A; Wiberg A; Khoonsari PE; Carlsson H; Herman S; Al-Grety A; Freyhult E; Olsson-Strömberg U; Burman J; Kultima K
    Lipids Health Dis; 2023 Jul; 22(1):97. PubMed ID: 37420217
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis.
    Baroncini D; Simone M; Iaffaldano P; Brescia Morra V; Lanzillo R; Filippi M; Romeo M; Patti F; Chisari CG; Cocco E; Fenu G; Salemi G; Ragonese P; Inglese M; Cellerino M; Margari L; Comi G; Zaffaroni M; Ghezzi A;
    JAMA Neurol; 2021 Jun; 78(6):726-735. PubMed ID: 33938921
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis.
    Boffa G; Massacesi L; Inglese M; Mariottini A; Capobianco M; Moiola L; Amato MP; Cottone S; Gualandi F; De Gobbi M; Greco R; Scimè R; Frau J; Zimatore GB; Bertolotto A; Comi G; Uccelli A; Signori A; Angelucci E; Innocenti C; Ciceri F; Repice AM; Sormani MP; Saccardi R; Mancardi G;
    Neurology; 2021 Feb; 96(8):e1215-e1226. PubMed ID: 33472915
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Changes in the Risk of Reaching Multiple Sclerosis Disability Milestones In Recent Decades: A Nationwide Population-Based Cohort Study in Sweden.
    Beiki O; Frumento P; Bottai M; Manouchehrinia A; Hillert J
    JAMA Neurol; 2019 Jun; 76(6):665-671. PubMed ID: 30882868
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial.
    Burt RK; Balabanov R; Burman J; Sharrack B; Snowden JA; Oliveira MC; Fagius J; Rose J; Nelson F; Barreira AA; Carlson K; Han X; Moraes D; Morgan A; Quigley K; Yaung K; Buckley R; Alldredge C; Clendenan A; Calvario MA; Henry J; Jovanovic B; Helenowski IB
    JAMA; 2019 Jan; 321(2):165-174. PubMed ID: 30644983
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term follow-up more than 10 years after HSCT: a monocentric experience.
    Frau J; Carai M; Coghe G; Fenu G; Lorefice L; La Nasa G; Mamusa E; Vacca A; Marrosu MG; Cocco E
    J Neurol; 2018 Feb; 265(2):410-416. PubMed ID: 29270686
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Autologous hematopoietic stem cell transplantation with reduced-intensity conditioning in multiple sclerosis.
    Shevchenko JL; Kuznetsov AN; Ionova TI; Melnichenko VY; Fedorenko DA; Kartashov AV; Kurbatova KA; Gorodokin GI; Novik AA
    Exp Hematol; 2012 Nov; 40(11):892-8. PubMed ID: 22771495
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Autologous Hematopoietic Stem-Cell Transplantation in Multiple Sclerosis: A Systematic Review and Meta-Analysis.
    Nabizadeh F; Pirahesh K; Rafiei N; Afrashteh F; Ahmadabad MA; Zabeti A; Mirmosayyeb O
    Neurol Ther; 2022 Dec; 11(4):1553-1569. PubMed ID: 35902484
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MRI and CSF oligoclonal bands after autologous hematopoietic stem cell transplantation in MS.
    Saiz A; Carreras E; Berenguer J; Yagüe J; Martínez C; Marín P; Rovira M; Pujol T; Arbizu T; Graus F
    Neurology; 2001 Apr; 56(8):1084-9. PubMed ID: 11320183
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinical outcome 6 years after autologous hematopoietic stem cell transplantation in multiple sclerosis].
    Saiz A; Blanco Y; Berenguer J; Gómez-Choco M; Carreras E; Arbizu T; Graus F
    Neurologia; 2008 Sep; 23(7):405-7. PubMed ID: 18726717
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort.
    Tilling K; Lawton M; Robertson N; Tremlett H; Zhu F; Harding K; Oger J; Ben-Shlomo Y
    Health Technol Assess; 2016 Oct; 20(81):1-48. PubMed ID: 27817792
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low intensity lympho-ablative regimen followed by autologous hematopoietic stem cell transplantation in severe forms of multiple sclerosis: A MRI-based clinical study.
    Curro' D; Vuolo L; Gualandi F; Bacigalupo A; Roccatagliata L; Capello E; Uccelli A; Saccardi R; Sormani MP; Mancardi G
    Mult Scler; 2015 Oct; 21(11):1423-30. PubMed ID: 25583838
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of autologous haematopoietic stem cell transplantation on disability and brain atrophy in secondary progressive multiple sclerosis.
    Mariottini A; Filippini S; Innocenti C; Forci B; Mechi C; Barilaro A; Fani A; Carlucci G; Saccardi R; Massacesi L; Repice AM
    Mult Scler; 2021 Jan; 27(1):61-70. PubMed ID: 32008439
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Self-reported changes in the expanded disability status scale score in patients with multiple sclerosis after autologous stem cell transplants: real-world data from a single center.
    Ruiz-Argüelles GJ; Olivares-Gazca JC; Olivares-Gazca M; Leon-Peña AA; Murrieta-Alvarez I; Cantero-Fortiz Y; Gomez-Cruz GB; Ruiz-Argüelles A; Priesca-Marin M; Ruiz-Delgado GJ
    Clin Exp Immunol; 2019 Dec; 198(3):351-358. PubMed ID: 31394007
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A real-world single-centre analysis of alemtuzumab and cladribine for multiple sclerosis.
    Bose G; Rush C; Atkins HL; Freedman MS
    Mult Scler Relat Disord; 2021 Jul; 52():102945. PubMed ID: 33901969
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Benefits of aHSCT over alemtuzumab in patients with multiple sclerosis besides disability and relapses: Sustained improvement in cognition and quality of life.
    Braun B; Fischbach F; Richter J; Pfeffer LK; Fay H; Reinhardt S; Friese MA; Stellmann JP; Kröger NM; Heesen C; Häußler V
    Mult Scler Relat Disord; 2024 Feb; 82():105414. PubMed ID: 38176284
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of Rituximab Treatment With Disability Progression Among Patients With Secondary Progressive Multiple Sclerosis.
    Naegelin Y; Naegelin P; von Felten S; Lorscheider J; Sonder J; Uitdehaag BMJ; Scotti B; Zecca C; Gobbi C; Kappos L; Derfuss T
    JAMA Neurol; 2019 Mar; 76(3):274-281. PubMed ID: 30615019
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.